| Pair Name | Sclareol, Cisplatin | ||
| Phytochemical Name | Sclareol (PubChem CID: 163263 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Sclareol, Cisplatin | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | ERCC1 | hsa2067 |
| Down-regulation | Expression | AKT1 | hsa207 | |
| Down-regulation | Expression | JUN | hsa3725 | |
| Down-regulation | Expression | SNAI1 | hsa6615 | |
| Down-regulation | Expression | MAPK8 | hsa5599 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| In Vivo Model | These mice were subcutaneously injected with A549 cells (6×10⁶ cells in 100 μL of PBS). | |||
| Result | Sclareol has potential as an adjuvant for the treatment in NSCLC patients with cisplatin resistance. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3β-AP1/Snail and JNK-AP1 pathways. Chem Biol Interact. 2020 Dec 1;332:109304. doi: 10.1016/j.cbi.2020.109304. | Click |
